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Abstract
Background: Do In Seung Gi-Tang (DISGT) is an herbal mixture of traditional Korean medicine that is composed of
Rheum undulatum Linne, Prunus Persica (L.) Batsch, Conyza canadensis L., Cinnamomum Cassia Presl, and Glycytthiza
uralensis Fischer (8: 6: 4: 4: 4 ratio). We investigated the effect of DISGT on vascular inflammation and lipid
accumulation in apolipoprotein E-deficient (ApoE−/−) mice.
Methods: ApoE−/− mice that were fed a high-fat diet (HFD) were treated with DISGT (300 mg/kg/day) or statin
(10 mg/kg/day) for 16 weeks. Serum lipid levels were analyzed. Oil Red O staining was used to evaluate
atherosclerotic lesions and lipid accumulation in the aorta and liver, respectively. The expression of adhesion
molecules (intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1], and E-selectin),
fatty acid synthase (FAS), adenosine monophosphate-activated protein kinase (AMPK), and acetyl-coA carboxylase
(ACC) in the aorta or liver tissues was measured by western blot analysis. Lipid synthesis and inflammatory
responses were assessed by immunohistochemistry and hematoxylin & eosin staining, respectively.
Results: Treatment of HFD-fed mice with DISGT significantly lowered body weight, liver weight, and the levels of
lipids, including total cholesterol, low-density lipoprotein-cholesterol, and triglycerides. Glucose levels were also
lowered. In the aorta, DISGT attenuated atherosclerotic lesions and reduced the expression of ICAM-1, VCAM-1, and
E-selectin. Moreover, DISGT decreased lipid accumulation, inflammatory responses, and FAS levels, and it activated
AMPK and reduced ACC expression in liver tissues.
Conclusions: The beneficial, anti-lipolytic, and anti-inflammatory effects of DISGT were mediated by the AMPK
pathway. As a result, the expression of inflammatory factors was reduced. Our data provide evidence that DISGT
may have strong therapeutic potential in treating vascular diseases, such as atherosclerosis.
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Background
Do In Seung Gi-Tang (DISGT; Tao He Cheng Qi-Tang;
Chinese) is used in traditional Korean medicine to treat
blood stasis by promoting blood circulation. Blood ex-
travasation in traditional Korean medicine refers to the
ability to encompass vascular diseases that are related to
hyperlipidemia, such as arteriosclerosis [1–5]. DISGT has
been shown to improve the impairment of acetylcholine-
induced vasorelaxation responses by inducing endothelial
nitric oxide synthase expression, thus reducing the
accumulation of atherosclerotic lesions in vivo [2]. As doc-
umented in Shang Han Lun, DISGT is five species com-
posed of Rheum undulatum Linne, Prunus Persica (L.)
Batsch, Conyza canadensis L., Cinnamomum Cassia Presl,
and Glycytthiza uralensis Fischer, that have various
pharmacological on the cardiovascular disease or meta-
bolic diaseas [1, 6, 7]. It has been reported to high-fat/
high-cholesterol diet-fed db/db mice and western diet fed
ApoE mice, DISGT decreased plasma glucose, cholesterol,
triglyceride, and LDL cholesterol levels and [8]. Further,
DISGT treat chronic hepatitis and amenorrhea. However,
the mechanisms involved and effectiveness of DISGT re-
main unclear in atherosclerosis.
Atherosclerosis is a chronic inflammatory disease that
involves increased total cholesterol (T-chole) levels,
blood monocyte recruitment, lipid deposition, and
macrophage foam cell formation [9, 10]. Recently, the
atherosclero-related disease protective potentive of
DISGT is suggest based on some studies. DISGT, has
been shown to attenuate the increases in T-chole that
are induced by a hypercholesterolemic diet in mices, and
this action may be due to the promotion of cholesterol
[1, 7]. These results show that DISGT may be useful in
the treatment of cardiovascular-metabolic disease. The
effects of adenosine monophosphate-activated protein
kinase (AMPK) on metabolically relevant organs and tis-
sues, such as the liver, skeletal muscle, adipose tissue,
and hypothalamus, are relatively well documented [11].
The notion that AMPK activation could be used to pro-
mote vascular health has only recently emerged. In vas-
cular tissues, AMPK activation appears to be a shared
molecular target [12, 13]. Therefore, AMPK activation
may improve vascular diseases, including atherosclerosis.
Traditional Korean herbal medicine has been widely
used in the treatment of atherosclerosis-related disorders
[14]. However, its therapeutic efficacies and mechanisms
of action are unclear. Several studies have suggested that
DISGT demonstrates therapeutic potential in cardiovas-
cular disease and atherosclerosis. In this study, we inves-
tigated the effects of DISGT on atherosclerosis-related
markers, including intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1),
and E-selectin, in high-fat diet (HFD)-induced apolipo-
protein E-deficient (ApoE−/−) mice. In addition, we
assessed the effect of DISGT on AMPK signaling, lipid
levels, atherosclerotic lesions, and liver histology in these
mice.
Methods
Preparation of DISGT (Table 1)
The herbs were purchased from Kwangmyeongdang
Medicinal Herbs Co. (Ulsan, Korea) and authenticated
based on their microscopic and macroscopic characteris-
tics by the classification and identification committee of
the Korea Institute of Oriental Medicine (KIOM).
The formula of DIGST consists of five herbs, including
Rheum undulatum Linne (80 g), Prunus Persica (L.)
Batsch (60 g), Conyza canadensis L. (40 g), Cinnamomum
Cassia Presl (40 g), and Glycyrrhiza uralensis Fischer
(40 g), which were mixed and ground into a crude pow-
der. The total mixure (260 g) was boiled in distilled water
(1:10, v/v) at 100 °C for 2 h and the extract was filtered, ly-
ophilized and subsequently stored at −20 °C. The yield of
DISGT aqueous extract was 11.25 % (w/w).
Experimental animals, diet, and treatments
Male 8 weeks old ApoE−/− mice on a C57BL/6 J back-
ground were obtained from SLC Inc., (Shizuoka, Japan).
They were housed under diurnal lighting conditions and
allowed access to food and tap water ad libitum. All ex-
perimental protocols involving the use of animals were
conducted in accordance with the National Institutes of
Health guidelines and approved (approve number; Kiom
13–037) by the Committee on Animal Care of the Korea
Institute of Oriental Medicine (KIOM).
Mice were divided into four groups: (1) Normal diet (ND;
n = 8), (2) HFD (41 % of total calories from fat; 0.21 % chol-
esterol; Research Diet, New Brunswick, NJ, USA) with sa-
line (n = 8), (3) HFD with 300 mg/kg DISGT (n = 8), and
(4) HFD with 10 mg/kg atorvastatin (statin; n = 8). DISGT
or statin was dissolved in water and then given orally every-
day over a 16-week period, during which the mice were fed
a HFD. Control mice received saline.
Analysis of serum markers
Blood samples were drawn from the aorta under light
anesthesia and stored on ice for 30 min before centrifuga-
tion at 13,000 rpm at 4 °C for 10 min, after which they
were stored at −80 °C. Serum levels of T-chole, high-
Table 1 Composition of Do In Seung Gi-Tang
Scientific name Herbal name Amount (g)
Prunus persica (L.) Batsch Persicae Semen,桃仁 60
Cinnamomum cassia Presl Cinnamomi Ramulus,桂枝 40
Glycyrrhiza uralensis Fisch Licorice,甘草 40
Mirabilite Natrii sulfas,芒硝 40
Rheum palmatum Linne Rhei Rhizoma,大黃 80
Park et al. BMC Complementary and Alternative Medicine  (2016) 16:352 Page 2 of 10
density lipoprotein cholesterol (HDL), low-density
lipoprotein cholesterol (LDL), triglyceride (TG), glucose,
alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), and creatinine were measured with an auto-
matic analyzer (Hitachi Co., Tokyo, Japan).
Atherosclerotic lesion analysis
Mice were anesthetized and euthanized after 16 weeks
of HFD or ND. The aortas were washed with
phosphate-buffered saline (PBS) and then fixed with
10 % paraformaldehyde overnight. The adventitia was
cleaned thoroughly under a dissecting microscope,
and fixed aortas were stained with Oil Red O stock
solution (0.3 %) for 1 h. Atherosclerotic lesion areas
were quantified using the isolution full-image analysis
software (Image and Microscope Technology, Vancouver,
Canada).
Histopathology
Mice were deeply anesthetized with sodium thiopental
and subsequently perfused with cold PBS, followed by
fixation with 10 % (w/v) paraformaldehyde overnight.
Hematoxylin and Eosin (H&E): Livers were embedded in
paraffin and sectioned serially at 4 μm. The sections
were stained with H&E. The sections were stained with
H&E as described previously [15]. Immunohistochemistry:
Livers were removed and fixed in the same solution
for 24 h at 4 °C. Fixed aortas were frozen and stored
at −80 °C. Sections that were 10-μm thick were
sliced from frozen tissues and then immunostained
with antibodies against fatty acid synthase (FAS;
Novus Biologicals; Littleton, CO, USA). After add-
itional incubation with the secondary antibody, the
chromogen, 3-amino-9-ethylcarbazole, was added to
the sections (Vector Laboratories; Burlingame, CA,
USA). Reactions with 3,3’-diaminobenzidine substrate
(Vector Laboratories) were performed for color de-
velopment, and the stained sections were then ana-
lyzed by light microscopy scanner (3D HISTECH,
Budapest, Hungary).
Western blot analysis
Aortas were homogenized in Tissue protein extraction
reagent (Thermo Scientific; Pittsburgh, PA, USA), which
was supplemented with a 1 % phosphatase inhibitor
cocktail (Sigma-Aldrich Chemical Co.; St. Louis, MO,
USA) and protease inhibitors (Roche Applied Science;
Basel, Switzerland). The recovered proteins were isolated
from aortic tissues, separated by 10 % sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and then
transferred onto nitrocellulose membranes (Amersham
Biosciences; Piscataway, NJ, USA), according to standard
techniques. Blots were probed with primary antibodies
directed against VCAM-1 (Santa Cruz Biotechnology;
Santa Cruz, CA, USA), ICAM-1, E-selectin, AMPK,
phosphorylated (p)-AMPK, acetyl-COA carboxylase
(ACC), p-ACC (Cell Signaling Technology; Beverly, MA,
USA), or FAS. This was followed by incubation with the
secondary antibody conjugated to horseradish peroxid-
ase (Cell Signaling). Bound secondary antibodies were
detected by chemiluminescence, as generated by the
peroxidase reaction, and they were measured with an
ImageQuant LAS 4000 apparatus (GE Healthcare Life
Sciences; Buckinghamshire, UK). The membranes were
then reprobed with an anti-β-actin antibody (Cell Signaling)
as the internal sample control.
Quantitative high-performance liquid chropmatography
analysis
The sample was analyzed by reverse phase-high per-
formance liquid chromatography using Waters e2695 li-
quid chromatography system (Waters Co., Milford, MA,
USA), equipped with a Waters 2998 photodiode array
detector. Data processing was carried out with the
Empower software (Waters Co.). The Phenomenex Luna
C18 column (250 mm× 4.6 mm; particle size 5 μm;
Phenomenex, Torrance, CA, USA) was used as the sta-
tionary phase and 1 % (v/v) acetic acid aqueous solution
(A) and acetonitrile · acetic acid (99:1) (B) were used as
the mobile phase. The elution conditions involved hold-
ing the starting mobile phase at 90 % A and 10 % B and
applying a gradient of 0 % A and 100 % B for 50 min. A
wash with 100 % acetonitrile was applied for 10 min,
followed by equilibration at 90 % A and 10 % B for
10 min. The flow rate was 1.0 mL/min and the injection
volume for all the samples was 20 μL. Peaks were identi-
fied by comparing retention times and UV spectra with
those of commercial standards. Components were quan-
tified based on peak areas at 220 nm. Quantitation was
performed based on a mixture of external standards of
known concentration, which were analyzed in duplicate
before and after analyzing the samples. Peak areas were
used to calculate the quantities of compounds in the
samples. The calibration curves of the standards ranging
from 11.9 to 243 μg/mL (five levels) revealed good lin-
earity, with R2 values exceeding 0.999 (peak area vs. con-
centration). HPLC-grade reagents, acetonitrile and water
were obtained from J. T. Baker (Phillipsburg, NJ, USA).
Data analysis
Values are expressed as the mean ± standard error of the
mean (SEM). Statistical comparisons were performed
using unpaired Student’s t-tests and analysis of variance
(ANOVA) for repeated measures followed by post hoc
pairwise comparisons in SigmaPlot software version 13.0
(Systat Software Inc.; San Jose, CA, USA). Differences
were considered significant at p < 0.05.
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Results
Effect of DISGT on body weight, liver weight, and serum
parameters in HFD-induced ApoE−/− mice
The body weight, liver weight, and serum parameters were
measured in mice. HFD-fed ApoE−/− mice showed signifi-
cantly increased body weight compared with ND-fed mice
(34.8 ± 0.59 vs. 49.7 ± 1.16 g, p < 0.001). However, treat-
ment of HFD-fed mice with DISGT or statin decreased
the body weight (Fig. 1a-b and Table 2; 36.7 ± 2.48 or 42.2
± 1.24 g vs. HFD group; p < 0.001). Furthermore, the liver
weights showed an increased in the HFD-fed ApoE−/−
mice (p < 0.001), and the elevated liver weight was reduced
by DISGT (Fig. 1c and Table 2; p < 0.001, versus HFD
group). In addition, HFD-fed mice showed significantly
higher serum levels of T-chole, LDL, TGs, glucose, AST,
ALT, and creatinine than that of ND-fed mice. These
levels were all significantly reduced by DISGT or statin
treatment (Table 3).
Effect of DISGT on atherosclerotic lesions in aortas
The extent of atherosclerotic lesions in the aorta was de-
termined by isolution analysis, and it was confined to the
cross-section of the aortic root. Oli Red O staining was
used to detect atherosclerotic plaques. The aortic root le-
sion area was markedly increased in HFD-fed mice (27.72
± 2.87 mm2; p < 0.01), and it was significantly reduced by
treatment with DISGT or statin (7.24 ± 1.81 mm2 or 11.90
± 1.07 mm2; p < 0.01) (Fig. 2a and b). As demonstrated by
A
B C
Normal Diet High Fat Diet 
DISGT 
300 mg/kg statin 10 mg/kg 
Fig. 1 Effects of DISGT on body weights and liver weights. Mice (8 weeks old) were placed in four groups: normal diet (ND), high-fat diet (HFD),
HFD with 300 mg/kg Do In Seung Gi-Tang (DISGT), and HFD with 10 mg/kg atorvastatin (statin). Experiments were carried out for 16 weeks.
a Images of mice from all groups. b Body weights were measured every week for 16 weeks. c After 16 weeks of ND or HFD, liver tissues were
collected and washed with cold phosphate-buffered solution, after which they were weighed. Values are mean ± SEM. **p < 0.01, ***p < 0.001 vs.
ND; ###p < 0.001 vs. HFD
Table 2 Body weight and liver weight
DISGT Statin
ND HFD 300 mg/kg 10 mg/kg
Body weight (g)
Initial body weight 21.70 ± 0.64 20.20 ± 0.67 22.40 ± 0.57 22.80 ± 0.50
Final body weight 34.80 ± 0.59 49.70 ± 1.16*** 36.70 ± 2.48### 42.20 ± 1.24###
Body weight gain 13.10 ± 0.63 29.50 ± 0.98*** 14.30 ± 1.00### 19.40 ± 0.65###
Liver weight (g) 1.17 ± 0.05 3.48 ± 0.24*** 1.52 ± 0.13### 1.92 ± 0.10###
Abbreviations: HFD high-fat diet, DISGT Do In Seung Gi-Tang
All data represent mean values ± SEM (n = 8)
***p < 0.001, vs. ApoE−/− mice without HFD (ND; Normal diet)
###p < 0.001, vs. HFD-fed ApoE−/− mice (HFD)
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western blot analysis, the expression of ICAM-1, VCAM-
1, and E-selectin in HFD-fed mice was significantly in-
creased compared with that in ND-fed mice. In contrast,
DISGT- or statin-treated mice showed lower expression
levels of ICAM-1, VCAM-1, and E-selectin compared with
HFD-fed mice (Fig. 2c), and this decrease by DISGT was
statistically significant (Fig. 2d).
Histology of liver
The accumulation of lipids in the liver impairs hepato-
cyte function, which leads to hyperglycemia via hepatic
glucose production. The staining of liver tissues with
H&E and Oil Red O was analyzed. Lipid droplets accu-
mulated in the livers of HFD-fed mice, and this accumu-
lation was decreased with DISGT or statin treatment
Table 3 Lipid parameters
DISGT Statin
ND HFD 300 mg/kg 10 mg/kg
T-chole (mg/dL) 401.86 ± 21.18 1401.71 ± 69.66*** 951.43 ± 56.72### 1145.00 ± 75.60#
LDL (mg/dL) 71.86 ± 2.08 368.29 ± 17.88*** 244.14 ± 13.48### 316.33 ± 18.48#
HDL (mg/dL) 22.14 ± 1.27 11.71 ± 1.14*** 12.57 ± 1.15 13.17 ± 2.71
TG (mg/dL) 34.57 ± 2.51 278.71 ± 16.06*** 43.29 ± 13.11### 75.83 ± 2.42###
Glucose (mg/dL) 134.29 ± 4.40 422.71 ± 36.80*** 201.29 ± 12.79### 298.50 ± 12.83##
AST (U/L) 50.29 ± 7.06 571.57 ± 22.64*** 333.29 ± 25.70### 370.83 ± 12.62###
ALT (U/L) 29.86 ± 1.71 562.43 ± 14.32*** 247.86 ± 33.41### 277.00 ± 20.91###
Creatinine (mg/dL) 0.21 ± 0.02 0.35 ± 0.03** 0.17 ± 0.02### 0.25 ± 0.03
Abbreviations: HFD high-fat diet, DISGT Do In Seung Gi-Tang, T-chole total cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride,
AST aspartate aminotransferase, ALT alanine aminotransferase
All data represent mean values ± SEM (n = 8)
**p < 0.01, ***p < 0.001, versus ApoE−/− mice without HFD (ND)
#p < 0.05, ##p < 0.01, and ###p < 0.001, versus HFD-fed ApoE−/− mice (HFD)
A
B
Normal Diet High Fat Diet 
High Fat Diet
+ DISGT 300 mg/kg 
High Fat Diet












Fig. 2 Effect of DISGT on reducing aortic lesions and expression of adhesion molecules in the aorta. a The aorta was collected from HFD-fed mice
that were treated with DISGT or statin orally for 16 weeks. Representative photomicrographs of Oil Red O staining are shown. (Cross sections;
×100, above; ×200, under, magnification). b Quantification of Oil Red O-stained atherosclerotic lesion areas from each group. c Western blots of
ICAM-1, VCAM-1, and E-selectin. d Densitometric analysis showing the relative protein expression levels of ICAM-1, VCAM-1, and E-selectin that
were normalized to β-actin. Values are mean ± SEM. **p < 0.01, ***p < 0.001 vs. ND; #p < 0.05, ##p < 0.01, ###p < 0.001vs. HFD

























Fig. 3 Effect of DISGT on ameliorating liver steatosis in HFD-fed ApoE−/− mice. Liver tissues were fixed in 10 % formaldehyde, embedded in paraffin,
sectioned, and stained with (a) Oil Red O (×20, above; ×100, under, magnification) or (b) Hematoxylin and eosin (×100 magnification)
Normal Diet High Fat Diet DISGT 300 mg/kg statin 10 mg/kg A
B
DISGT (mg/kg)





Fig. 4 Effect of DISGT on attenuating fatty acid synthase (FAS) expression in the livers of HFD-fed ApoE−/− mice. a Expression of lipogenic
enzymes, such as FAS, and inflammatory factors in the livers and aortas of HFD-fed mice, respectively. b Protein expression levels of FAS were
determined by western blot analysis. Values are mean ± SEM. ***p < 0.001 vs. ND; ##p < 0.01, ###p < 0.001vs. HFD
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(Fig. 3a). Furthermore, DISGT reduced sizes of adipocy-
tesation and inflammation, as demonstrated by de-
creased H&E staining (Fig. 3b).
Effect of DISGT on FAS expression
FAS is involved in the synthesis of fatty acids and TGs,
and it is known to be upregulated in HFD-fed mice. The
expression of FAS in liver tissues of HFD-fed mice was
reduced by DISGT or statin treatment (Fig. 4a). Also,
the effect of DISGT on decreasing FAS expression was
further confirmed by western blotting (Fig. 4b).
Effect of DISGT on the expression of the AMPK pathway
in liver tissues
AMPK plays a crucial role in fatty acid metabolism, and
it has demonstrated potential therapeutic impact in ath-
erosclerosis. The protein levels of AMPK and ACC were
assessed in liver tissues of ApoE−/− mice. Interestingly,
DISGT increased the phosphorylation of AMPK in liver
tissues. ACC phosphorylation, which is an index of
AMPK activation, was also consistently detected in these
tissues (Fig. 5a and b).
Quantitative high-performance liquid chropmatography
analysis of DISGT
The HPLC analysis of the DISGT revealed three peaks
matching those of the commercial standards cinnamic acid,
glycyrrhizic acid, and amygdalin with retention times of ap-
proximately 20.5 min, 23.0 min, and 33.5 min, respectively
(Fig. 6). The DISGTcontained 0.104 ± 0.006 mg/g cinnamic
acid, 1.901 ± 0.013 mg/g glycyrrhizic acid, and 2.566 ±
0.007 mg/g amygdalin (Table 4).
Discussion
The Korean herbal medicine DISGT, has been shown to
prevent vascular or liver inflammatory responses and
lipid deposition in vivo. Currently, it is used to treat
blood stasis by promoting blood circulation. In this
















Fig. 5 Effect of DISGT on adenosine monophosphate-activated protein kinase (AMPK) signaling pathway components. a Western blots of
phosphorylated AMPK (p-AMPK), phosphorylated acetyl-COA carboxylase (p-ACC), AMPK, and ACC. b Densitometric analysis showing the relative
protein expression levels of p-AMPK and p-ACC that were normalized to total AMPK and total ACC, respectively. Values are mean ± SEM. Values
are mean ± SEM. *p < 0.05, ***p < 0.001 vs. ND; #p < 0.05, ##p < 0.01, ###p < 0.001vs. HFD
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Our findings show that DISGT reduced body weight,
liver weight, and the serum levels of T-chole, LDL, TGs,
and glucose, in HFD-fed ApoE−/− mice. No changes in
HDL were observed. DISGT also significantly attenuated
the severity of atherosclerotic lesions and reduced the
expression of adhesion molecules in the aortas of HFD-
fed mice. In addition, the increased accumulation of in-
flammatory cells and hepatic steatosis in the liver tissues
were observed in the HFD group compared with the ND
group. However, DISGT inhibited these changes in
HFD-fed mice. Importantly, the AMPK pathway is a
regulator of metabolic homeostasis. DISGT markedly re-
duced the expression of FAS and p-ACC and increased
the expression of p-AMPK. These data suggest that
DISGT activates AMPK to exert anti-atherosclerotic
effects.
Because AMPK is a cellular energy sensor, understand-
ing the mechanism by which hepatic AMPK coordinates
hepatic energy metabolism is important. The dysfunc-
tion of the AMPK signaling pathway is involved in the
development of various cardiovascular diseases, includ-
ing atherosclerosis [9, 16]. AMPK inhibits the expression
of adhesion molecules and E-selectin in endothelial cells
that have been exposed to hydrogen peroxide, tumor ne-
crosis factor-alpha, or fatty acids [12, 17, 18]. In the liver,
AMPK activation stimulates fatty acid oxidation and in-
hibits lipogenesis, and lipid metabolism is reduced by adi-
ponectin [17, 18, 19]. Recent studies have suggested that
AMPK is a therapeutic target of atherosclerosis, because it
reduces vascular inflammation and fatty acid synthesis to
attenuate atherosclerosis [13, 18, 20].
Many studies have focused on the effects of dietary fatty
acids or vascular inflammation on lipid and lipoprotein
metabolism with regard to the risk of atherosclerosis.
However, fatty acids can also influence a number of other
relevant mechanisms that are involved in atherosclerosis,
such as lipid peroxidation, vascular inflammation, and
hemostasis [21–23]. In our study, DISGT attenuated the
accumulation of lipids in the liver and the presence of ath-
erosclerotic lesions in the aorta. Furthermore, the expres-
sion levels of AMPK-regulated lipoxidation factors,
inflammatory compounds, and adhesion molecules were
significantly decreased in the livers and aortas of DISGT-
treated, HFD-fed mice. This indicates that DISGT acti-
vates AMPK, thereby preventing the vascular inflamma-
tory response and lipid deposition.
Interestingly, statins did not lower total cholesterol but
had a major effect on TG levels in the current study.
These results are different than those expected in
humans. Clinically established statins have long been
known to exert anti-atherosclerotic effects. However, re-
cent studies have suggested that the effects of statins on
cholesterol in mice are different than those in humans.











Fig. 6 HPLC chromatogram of a standard mixture (a) and DISGT (b) at 220 nm. Cinnamic acid (1), glycyrrhizic acid (2), and amygdalin (3) appeared
with retention times of approximately 20.5 min, 23.0 min, and 33.5 min, respectively
Table 4 Average contents of the reference compounds in
DISGT
Compound Average content (mg/g)
Cinnamic acid 0.104 ± 0.006
Glycyrrhizic acid 1.901 ± 0.013
Amygdalin 2.566 ± 0.007
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cholesterol levels in ApoE−/− mice. This can be explained
by the lack of ApoE, which is a ligand for the LDL recep-
tor and is necessary for LDL clearance. Thus, the
cholesterol-independent effects of statins can be more ef-
fectively studied in mice than in humans [23–25].
Cholesterol crystals have been reported to be the
metabolic signals that trigger sterile inflammation in ath-
erosclerosis [26]. Previous studies have shown that
AMPK is a key player in maintaining physiological pro-
cesses in the heart and vasculature [12, 27], and it regu-
lates lipoxidation genes [28]. Results from these studies
support our data and suggest that AMPK modulates the
effect of DISGT on lowering inflammation and lipid de-
position to reduce atherosclerosis. Most importantly,
DISGT protected the vasculature against the initiation
and development of atherosclerosis.
Conclusions
DISGT prevented the development of atherosclerotic le-
sions, the expression of vascular inflammatory markers,
and the accumulation of lipids in HFD-fed ApoE−/− mice.
This was associated with increases in AMPK levels.
Therefore, DISGT may exert its anti-atherosclerotic ef-
fects by activating AMPK. Moreover, DISGT has the po-
tential for use as a therapeutic drug for the treatment of
atherosclerosis. Further studies are needed to identify and
classify the active components of the herbal mixture and
clinical trial.
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